樂
樂觀
樂觀 · 25%PLRZ
$0.90
情境價格
$11.045
-0.519 (-4.70%)收盤時
Loading chart…
- 最高
- 11.590
- 開盤
- 11.590
- 成交量加權均價
- 11.21
- 成交量
- 7.75K
- 市值
- —
- 最低
- 11.000
- 成交金額
- 86.85K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
AI 分析 of Polyrizon Ltd (PLRZ)
買進Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
估值指標
Polyrizon Ltd（PLRZ）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。
Alphio AI 對 PLRZ 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
9.010-27NewsfilterPolyrizon Completes Patient Enrollment for NASARIX Clinical Study
9.009-22NASDAQ.COMPolyrizon Initiates Clinical Trial for Seasonal Allergic Rhinitis Treatment
- 8.509-04Newsfilter
Polyrizon Closes $4 Million Financing Round
8.509-03NASDAQ.COMPolyrizon Secures $4 Million Financing Through Direct Offering and Private Placement
- 8.509-02Newsfilter
Polyrizon Completes Clinical Site Contracts for NASARIX™ Study
PLRZ 常見問題 —— 由 Alphio AI 解答
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers.. It operates in the Healthcare sector.
Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
社群
更多 ↗暫無貼文
註冊或登入後參與討論相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。